EUVIMEDEUVIMED entdecken
Editorial

Ondansetron: A Novel Treatment to Reduce the Severity of Neonatal Opioid Withdrawal Syndrome?

Susan Givens Bell

Neonatal Network · 2025

DOI: 10.1891/nn-2025-0005 ↗

Kurz gefasst

Editorial in der Zeitschrift Neonatal Network, 2025. Verfasst von Susan Givens Bell. Beteiligte Einrichtung: NICU, Kaiser Permanente Sunnyside Medical Center, Clackamas, OR, USA sjgbell@gmail.com. Hauptthemen laut MEDLINE: Analgesics, Opioid, Neonatal Abstinence Syndrome, Ondansetron. Die Arbeit nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A transition from a pharmacological-based model of care, such as Finnegan scoring, to a behavioral-based model, such as the Eat–Sleep–Console, for newborns experiencing neonatal abstinence syndrome (NAS) or neonatal opioid withdrawal syndrome (NOWS) has resulted in shorter lengths of stay and a decreased need for pharmacological management. However, many newborns continue to be exposed to opioids. Use of opioids for NAS/NOWS prolongs the length of stay and often the separation of mothers and their newborns as well. Additionally, opioids may have detrimental neurodevelopmental consequences for newborns. Researchers are seeking safe and effective pharmacological adjuncts to behavioral-based NAS/NOWS management. Could ondansetron be an answer? This column provides a brief review of a meta-analysis supporting the benefits of a behavioral approach to NOWS, a discussion about why ondansetron may be useful in NOWS, an overview of a pharmacokinetic study of ondansetron in mother–infant dyads, and a review of a recently published clinical trial of ondansetron for NOWS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Analgesics, OpioidNeonatal Abstinence SyndromeOndansetronFemaleHumansInfant, NewbornMeta-Analysis as Topic

Stichwörter der Autor:innen

NICU careevidence-based practiceneurologypharmacologyresearch

Substanzen

Analgesics, OpioidOndansetron

Autor:innen und Institutionen

  • NICU, Kaiser Permanente Sunnyside Medical Center, Clackamas, OR, USA sjgbell@gmail.com.

Zitieren

APA

Bell, S. G. (2025). Ondansetron: A Novel Treatment to Reduce the Severity of Neonatal Opioid Withdrawal Syndrome?. Neonatal Network. https://doi.org/10.1891/nn-2025-0005

Vancouver

Bell SG. Ondansetron: A Novel Treatment to Reduce the Severity of Neonatal Opioid Withdrawal Syndrome?. Neonatal Network. 2025. doi:10.1891/nn-2025-0005

BibTeX
@article{Bell2025,
  author = {Bell, Susan Givens},
  title = {Ondansetron: A Novel Treatment to Reduce the Severity of Neonatal Opioid Withdrawal Syndrome?},
  journal = {Neonatal Network},
  year = {2025},
  doi = {10.1891/nn-2025-0005}
}
Kostenlos starten →